GlassScriptPhysician profile
Martha E Reyes
NPI 1477043594
$1,655.89
in general payments reported to CMS, 2019-2025
18 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.09 · 2022: $134 · 2023: $118 · 2024: $113 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $284.79 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $273.73 | 2022-2025 | Zepbound, Mounjaro, Kisunla |
| Phathom Pharmaceuticals, INC. | $238.34 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.95 | 2025 | Xifaxan |
| Pfizer INC. | $100.37 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $100.23 | 2022-2023 | |
| Exact Sciences Corporation | $93.89 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $90.51 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.62 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $47.85 | 2021-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Inspire Medical Systems, INC. | $35.27 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $32.44 | 2024-2025 | Shingrix |
| Astellas Pharma US INC | $30.59 | 2025 | Veozah |
| Globus Medical, INC. | $28.87 | 2025 | Senza |
| Janssen Pharmaceuticals, INC | $18.34 | 2023 | Xarelto |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.03 | 2025 | Repatha, Otezla |
| Exeltis, USA INC. | $15.12 | 2025 | Slynd |
| Smith+Nephew, INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.